Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Forteo (teriparatide injection) is a recombinant form of human parathyroid hormone (PTH 1–34) indicated for the treatment of osteoporosis in adults at high risk for fracture. It stimulates new bone formation by activating osteoblasts more than osteoclasts, leading to increased bone mineral density (BMD) and strength. Forteo is approved for use in postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis, and both sexes with glucocorticoid-induced osteoporosis who are at high fracture risk or have failed other therapies.
Fact Table | |
Formula | C181H291N55O51S2 |
License | US FDA (2002); EMA |
Bioavailability | ~95% (subcutaneous) |
Legal status | Prescription only |
Chemical Name | Teriparatide (recombinant human parathyroid hormone 1-34) |
Elimination half-life | ~1 hour (subcutaneous injection) |
Dosage (Strength) | 20 mcg/day (pen delivers 28 doses; 600 mcg/2.4 mL) |
Pregnancy | Category C – risk cannot be ruled out |
Brands | Forteo, Terifrac (India), Bonsity (biosimilar) |
Protein binding | Not protein-bound; rapidly cleared |
PubChem CID | 16132397 |
MedlinePlus | a605030 |
ChEBI | CHEBI:75039 |
ATC code | H05AA02 |
DrugBank | DB06285 |
KEGG | D04572 |
Routes of administration | Subcutaneous injection (abdomen or thigh) |
Forteo is administered subcutaneously once daily at a dose of 20 mcg, typically in the thigh or abdomen.
Patients should be instructed on proper self-injection technique and use of the pen. Calcium and vitamin D supplementation should be provided as needed.
Each 80 mcL dose contains:
Inactive ingredients:
Forteo is contraindicated in patients with:
Boxed Warning: In animal studies, teriparatide caused osteosarcoma. While the relevance to humans is unknown, use is limited to a lifetime maximum of 2 years.
Use caution in patients with urolithiasis, as teriparatide may raise serum calcium levels. Monitor serum calcium, urinary calcium excretion, and orthostatic blood pressure, particularly in the first weeks of therapy. Avoid use in patients at increased baseline risk of osteosarcoma. Not recommended in children or young adults with open epiphyses.
Common and potential side effects include: